Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

NCT04668690 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

193

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Mitoxantrone Hydrochloride Liposome Injection
DRUG: Chidamide

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.